The MASH market's potential can only be unlocked by a scalable, non-invasive diagnostic. Biopsies are not feasible for a 90-million-person potential market. Diagnostics are essential for identifying patients and monitoring the efficacy of expensive new treatments, a key requirement for all stakeholders.
GenFit operates in a rare position for a biotech company by fully funding its three Phase 2 programs through royalty streams from a partnership with Ipsen and revenue from its commercialized MASH diagnostic. This model avoids shareholder dilution and reduces financial risk, providing significant operational stability.
GenFit's CEO reveals a fluid capital markets strategy. The company delisted from US exchanges due to high costs and low news flow but is now considering a return as its pipeline advances. This demonstrates that a public listing is viewed as a strategic option to be utilized when conditions are optimal, not a permanent necessity.
The MASH diagnostic's value extends beyond clinical utility. It serves the needs of multiple stakeholders: payers avoid wasting money, drug manufacturers ensure their products reach the right patients, and prescribers make data-driven decisions. This multi-stakeholder alignment is key to its adoption.